Aortic thrombosis in a neonate with hereditary antithrombin III deficiency: successful outcome with thrombolytic and replacement treatment.
We report the case of a newborn male who presented an aortic thrombosis during the neonatal period and was subsequently diagnosed as having antithrombin III (AT III) hereditary deficiency type I. This hypercoagulable condition is known to predispose young adults to venous thrombosis, but in our patient the primary thrombotic incident affected the arterial vessels within the first few days of life. Combined treatment with thrombolytic agents and AT III concentrates recovered aortic permeability, suggesting that the use of AT III may be beneficial for the treatment of thrombotic complications during the first few days of life.
Sánchez
J
J
Haematology Department, University Hospital Reina Sofia, Córdoba, Spain.
Velasco
F
F
Alvarez
R
R
Román
J
J
Torres
A
A
D015901:Angiography, Digital Subtraction; D000925:Anticoagulants / Q000627:therapeutic use*; D000990:Antithrombin III / Q000627:therapeutic use*; D020152:Antithrombin III Deficiency; D001011:Aorta / Q000503:physiopathology*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008297:Male; D013924:Thrombophlebitis / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D000990:Antithrombin III; D006493:Heparin; D014568:Urokinase-Type Plasminogen Activator